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ABSTRACT 18 
The transport of nucleobases and nucleosides in protozoan parasites is known to be performed 19 
by Equilibrative Nucleoside Transporter (ENT) family members, including the extensively 20 
studied P1 and P2 nucleoside transporters of T. brucei bloodstream forms. Studies with P2 21 
knockout parasites suggested the existence of as yet uncharacterised purine transport 22 
mechanisms in these cells. Here, we deleted several ENT genes, in addition to P2, including 23 
an array comprising three genes encoding for high-affinity broad-selectivity nucleobase 24 
transporters - the longest multi-gene locus deletion in T. brucei to date. It was verified that 25 
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none of them appreciably contributed to the transport of hypoxanthine in bloodstream forms 26 
grown axenically in HMI-9 medium, which was mainly performed by a previously not 27 
described hypoxanthine-specific transporter (HXT1) with a Km of 22 ± 1.7 µM and Vmax of 28 
0.49 ± 0.06 pmol(107 cells)-1s-1. The uptake of adenine was also assessed in the knockout cells 29 
and was performed by a highly specific adenine transporter (ADET1) with a Km of 573 ± 62 30 
nM and Vmax of 0.23 ± 0.06 pmol(107 cells)-1s-1. Neither HXT1 nor ADET1 displayed any 31 
affinity for other natural purines or pyrimidines and could not be completely inhibited by 32 
hypoxanthine or adenine analogues. These carriers may be the final pieces in the substantial 33 
transporter array trypanosomes can employ to fine-tune the uptake of purines from diverse 34 
environments during their life cycles, and may be encoded by genes other than those of the 35 
ENT family.  36 
 37 
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 40 
1. INTRODUCTION 41 
 In higher eukaryotes, transport of nucleobases and nucleosides occurs via the 42 
concentrative nucleoside transporter (CNT, SLC28) or equilibrative nucleoside transporter 43 
(ENT, SLC29) families. Although these families have overlapping substrate specificities, they 44 
are structurally and physiologically unrelated: CNTs have 13 transmembrane domains 45 
(TMDs) and are sodium- or proton- symporters, which mediate the transport of nucleosides in 46 
an unidirectional energy-costly way, whereas ENTs are formed by 11 TMDs and are passive 47 
transporters that conduct substrates along the concentration gradient [1-3]. To date, all 48 
nucleoside and nucleobase transporters of parasitic protozoa were members of the ENT 49 
family, although they are proton symporters, able to concentrate the substrates inside the cell 50 
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[1, 4-6]. Other nucleobase transporter families are NAT, PRT and PUP [7] but, like CNTs, 51 
none of these have been found in protozoan genomes. 52 
 The best characterized parasites in terms of purine and pyrimidine transport are 53 
Trypanosoma brucei, the causative agent of Human African Trypanosomiasis (HAT; sleeping 54 
sickness), and Leishmania spp., causative agents of leishmaniasis. These parasites are known 55 
to express ENT family transporters for the uptake of nucleobases and/or nucleosides, which is 56 
an essential function because they are unable to synthesize purines de novo, relying on 57 
salvage from the host environment [1, 8, 9]. Due to this dependence on transport, several 58 
pharmacological approaches have focused on purine transporters as drug carriers for the 59 
treatment of parasitic infections, especially HAT [10-14]. 60 
 During its life cycle, T. brucei differentially expresses several mechanisms for the 61 
uptake of purine nucleosides and/or nucleobases. The P1 transport activities were reported to 62 
be encoded by a tandem repeat of six genes on chromosome 2 (NT2 - NT7); all these carriers 63 
were shown to have affinity for inosine and adenosine and some of them also displayed a 64 
certain level of affinity for hypoxanthine when expressed in oocytes of Xenopus laevis [15]. 65 
Two more P1-type transporters, NT9 and NT10, were reported to be specifically expressed in 66 
short-stumpy bloodstream forms [16] and procyclic forms (stage in the mid-gut of the tsetse 67 
fly) [8], respectively, whereas the TbAT1/P2 aminopurine transporter is only expressed in 68 
long-slender bloodstream forms [17, 18]. 69 
 The long-slender bloodstream forms further express two purine nucleobase 70 
transporters, H2 and H3 [10, 19], and the procyclic forms also express two purine nucleobase 71 
transporters, H1 and H4 [4, 20]; these transporters are believed to be encoded by a tandem 72 
repeat of NT8 on chromosome 11 [20, 21]. The function of the last three members of the ENT 73 
family is not yet clear, although one report suggest that NT11.1, NT11.2 and NT12 transport 74 
both nucleobases and the drug pentamidine [22]; to date, our own investigations have not 75 
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been able to confirm this. As the ENT transporters from T. brucei and from Leishmania spp. 76 
have now been cloned and at least partially characterized, we have previously argued that the 77 
observed pyrimidine nucleobase transport activities in these species must be mediated by 78 
members of a different, as yet unidentified, transporter family [23, 24]. 79 
 The interest on purine transporters in T. brucei increased dramatically when it was first 80 
reported that parasites resistant to melarsoprol, a first-line drug for treatment of late stage 81 
HAT, lack a purine transport activity, which was found to be TbAT1/P2 [17, 25-27]. 82 
Moreover, TbAT1/P2 was also found to efficiently transport pentamidine [17, 28] and is the 83 
main transporter of the veterinary trypanocide diminazene [29-31].  84 
 The binding model for P2 shows that its specificity for aminopurines is determined by 85 
the importance of hydrogen bonds formed between N1 and C6-NH2 of the purine ring and the 86 
transporter binding site, along with interactions between the transporter and N9 [18]. This 87 
affinity for a motif NH2─C(R1)═N(R2) also explains the affinity of P2 for diamidine drugs, 88 
such as Pentamidine, Melarsoprol and Diminazene [32, 33]. Additionally, two other 89 
transporters with high (HAPT1) and low (LAPT1) affinity for pentamidine have been 90 
reported to interact with diamidine drugs [34, 35]. More recently, the HAPT1 activity was 91 
found to be encoded by the gene TbAQP2, an aquaglyceroporin [36, 37]. 92 
 Several studies have focused on P2 as a carrier for new drugs containing melamine-93 
based units. Interestingly, however, the affinity of the drugs for P2 was not the sole 94 
determinant for their trypanocidal effects, and TbAT1/P2 knockout parasites were also able to 95 
transport these molecules and keep their IC50 values in a low micromolar range [38-40], 96 
evidencing the presence of extra transporters with the ability to transport purines and purine-97 
like molecules [1, 38, 39]. Indeed, unpublished data from the Barrett group suggested the 98 
expression of an adenine-sensitive, inosine- and hypoxanthine-insensitive mechanism for (low 99 
affinity) adenosine uptake in TbAT1/P2 knockout bloodstream forms [41]. 100 
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 In the light of all these studies, we decided to investigate whether T. brucei expresses 101 
additional purine nucleobase transporters that have not yet been reported. In order to eliminate 102 
some background transport of nucleobases, we knocked out the three genes known to encode 103 
high-affinity nucleobase transporters, from the TbAT1/P2-knockout cell line, and used this 104 
new lineage as the parental cells for the further knockout (KO) of NT11 and NT12. We 105 
verified that none of the deleted transporters are the main purine carriers in cultured 106 
bloodstream forms, and describe the existence of two new and highly specific purine 107 
transporters, transporting adenine and hypoxanthine. By the process of elimination we 108 
conclude that these newly discovered adenine and hypoxanthine transporters are most likely 109 
not members of the ENT family and may therefore indicate the existence of a new transporter 110 
family in pathogenic protozoa. 111 
  112 
2. MATERIALS AND METHODS 113 
2.1. Parasites and culture media 114 
 Bloodstream forms of s427 and TbAT1-KO and its derived clonal lines were 115 
cultivated in HMI-9 supplemented with 10% of foetal bovine serum (FBS; Gibco) as 116 
described [42]. When necessary, 40 µM of adenosine was added to the culture to avoid 117 
metabolic limitations. 118 
 Alternatively, parasites were cultivated in Creek’s Minimum Medium (CMM) [43] 119 
with modifications: instead of Gold Serum, we used standard FBS and supplemented the 120 
medium with 100 µM each of arginine, leucine, methionine, phenylalanine, tryptophan and 121 
tyrosine, and 40 µM of adenosine as purine source. T. brucei s427 were kept in serial passage 122 
in CMM for at least two weeks prior their use in uptake assays. 123 
 124 
2.2. Generation of T. brucei knockout lineages 125 
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2.2.1. Knockout of high-affinity nucleobase transporters cluster 126 
 The high-affinity nucleobase transporters described independently by Burchmore et al. 127 
(2003b) and Henriques et al. (2003) are located in a tandem array on chromosome 11 (Tritryp 128 
Tb927.11.3610, Tb927.11.3620 and Tb927.11.3630), which enabled us to delete all three 129 
genes at the same time, similar to what was done with glucose transporters in Leishmania 130 
mexicana [44]. In order to achieve this, specific upstream and downstream regions were 131 
chosen: due the fact the UTR before Tb927.11.3610 is short (292 base pairs; bp) and very 132 
similar to the other two UTRs between the nucleobase transporter sequences, we cloned a 133 
fragment (373 bp) consisting of the end of the sequence of the 40S ribosomal protein 134 
(Tb927.11.3600) upstream of Tb927.11.3610 and the first 101 bp of the UTR (Figure 1a), 135 
using primers HDK791 and HDK792, which contain restriction sites for PvuII and HindIII, 136 
respectively (a complete list of primers is given in Supplementary Table S1). The same logic 137 
was used to design the 3’ flank of the cassette, for which 269 bp at the end of the UTR after 138 
Tb927.11.3630 and the first 213 bp of Tb927.11.3640 were cloned using primers HDK905 139 
and HDK906, containing the restriction sites for BamHI and SbfI, respectively. The reactions 140 
were performed using a high-fidelity DNA polymerase (as described above) and 5 ng of 141 
genomic DNA of the Lister s427 wildtype strain. The PCR products were digested overnight 142 
with the appropriated enzymes and ligated into a pyrFEKO vector. The final vector was 143 
digested with PvuII and SbfI to release the KO cassette, and AclI to cleave the β-lactamase 144 
gene and facilitate the visualization of the band of interest. The digestion product was run in 145 
1% agarose gel, and the band of interest purified and transfected into TbAT1-KO [27], 146 
generating TbNBT-KO, which lacks all the confirmed T. brucei nucleobase transporters.  147 
 The TbNBT-KO line was cloned by limiting dilution and confirmed by the absence of 148 
amplification of the ORF of the nucleobase transporters with primers HDK901 and HDK902. 149 
As an internal control, each reaction contained primers (MB173 and MB174) to amplify a 150 
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fragment of actin, confirming the presence of DNA in the reaction. After the confirmation of 151 
the gene deletion, the resistance genes were removed by transient expression of Cre 152 
recombinase [45], enabling the reuse of the markers in the further knockouts. 153 
  154 
 2.2.2. Knockout of AT-A and AT-E 155 
 Using the TbNBT-KO clone as parental cell line, we deleted AT-A (NT11; 156 
Tb927.9.15980) and AT-E (NT12; Tb927.3.590), generating two new cell lines: TbNBT/AT-157 
A-KO and TbNBT/AT-E-KO. To do so, UTRs upstream and downstream the target genes 158 
were amplified by PCR and cloned into the vector pGL1688, based on pTBT [46] containing 159 
either a Hygromycin or Puromycin resistance cassette. The KO cassettes were released from 160 
the vector using NotI and XhoI, purified and introduced into TbNBT-KO, yielding single and 161 
double knockout strains after one or two rounds of transfection, respectively. Transfectants 162 
were cloned and verified by PCR prior to further use. 163 
 164 
2.3. Uptake assays 165 
 Uptake of [3H]-Hypoxanthine (Perkin-Elmer; 12.8 Ci/mmol) and [3H]-Adenine 166 
(Perkin-Elmer; 40.3 Ci/mmol) were performed as described previously [47]. 1×107 parasites 167 
were incubated with buffer containing 0.1 µM of radiolabelled substrate, in the presence or 168 
absence of inhibitor. After a predetermined period of time, the reaction was stopped by the 169 
addition of 2 mM ice-cold unlabelled substrate (hypoxanthine or adenine, as appropriate) and 170 
cells were immediately centrifuged through an oil layer. Cell pellets were lysed with 2% SDS 171 
for at least 1 h under agitation, and then incubated with scintillation fluid (Scintlogic U, 172 
Lablogic) overnight. Samples were read using a Hidex 300SL scintillation counter. 173 
Background radiation was determined by counting vials to which no cells or radiolabel was 174 
added. Radiolabel associated with the cell pellet but not internalised was determined by 175 
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including saturating levels of non-radiolabelled substrate in the assay buffer; the average of 176 
three such determinations was subtracted from each data point in the assay, as described [47]. 177 
 Km values for hypoxanthine and adenine transporters were determined by incubation of 178 
parasites with 0.1 µM of radiolabelled substrate in the presence of increasing concentrations 179 
of unlabelled substrate for one minute. Ki values for hypoxanthine and adenine analogues 180 
were calculated using the Cheng-Prusoff equation: Ki = IC50/(1+(L/Km)), where L represents 181 
the radiolabel concentration [48]. The IC50 was obtained by a non-linear regression of the 182 
inhibition curve for each inhibitor using GraphPad Prism 5, using an equation for a sigmoid 183 
line with variable slope. The same software was used for ANOVA test and to calculate linear 184 
regressions and Km and Vmax values, using the Michaelis-Menten equation V0 = 185 
Vmax([substrate]/([substrate)+Km)). Student’s T-test was performed in Microsoft Excel. 186 
 Based on the Ki obtained, the Gibbs free energy (ΔG0) was calculated using the 187 
equation ΔG0 = −RTln(Ki), in which R is the gas constant and T is the absolute temperature. It 188 
should be noted that these equations apply to competitive inhibitors, which is likely to be the 189 
case given that the inhibitors were close structural analogues of the radiolabelled substrates 190 
and the Hill slopes calculated for both HXT1 and ADE1 were consistently near −1 upon 191 
inhibition [47]. 192 
 Hypoxanthine and adenine analogues were diluted either in assay buffer or in DMSO, 193 
and then further diluted in assay buffer for the assayed concentrations. Whenever DMSO was 194 
present in the reaction, its concentration was kept below 1% in order to avoid any cell 195 
membrane damage during the assay. 196 
 197 
3. RESULTS 198 
3.1 A new hypoxanthine-specific transporter is the main responsible for hypoxanthine uptake 199 
in Trypanosoma brucei axenic bloodstream forms 200 
9 
 
 Constructs for the replacement of the NT8.1 - NT8.3 locus with antibiotic resistance 201 
cassettes were designed and constructed as described, above, in Methods section 2.2.1, and 202 
are depicted in Figure 1a. The knockout of the three high-affinity nucleobase transporter 203 
genes was confirmed by PCR (Figure 1b) and shows it is possible to knockout a ~7.5 kb 204 
genomic locus using a cassette of ~2.5 kb, which is, to our knowledge, the longest multi-gene 205 
locus deletion yet reported for T. brucei.  206 
 It should be noted that 40 µM of adenosine was added to the culture medium during 207 
the generation and selection of the TbNBT-KO clones, in case the clones failed to retain 208 
hypoxanthine transport activity. However, we assessed the transport of 0.1 µM of [3H]-209 
Hypoxanthine in the TbNBT-KO cells and found that parasites were still transporting 210 
hypoxanthine, with a linear phase lasting for at least 2 minutes and a rate of 0.0023 ± 0.0003 211 
pmol(107 cells)-1s-1 (n=6); the addition of 1 mM of unlabelled hypoxanthine completely 212 
abolished the transport, evidencing that this uptake mechanism is saturable (Figure 2a). 213 
 Moreover, the reduction in hypoxanthine transport by TbNBT-KO cells was very 214 
modest, on average approximately 15% compared to the TbAT1-KO control (4 pairwise 215 
experiments), and statistically non-significant (P>0.55, Paired Student’s T-test; Figure 2b), 216 
revealing that, under standard culture conditions, these three nucleobase transporter genes 217 
were not the main ones responsible for the uptake of hypoxanthine (Figure 2a), which is 218 
present in HMI-9 at 1 mM as sole purine source (apart from small quantities of purines in the 219 
serum).  220 
 As the deletion of the NT8 cluster barely reduced hypoxanthine transport rates, we 221 
hypothesized that either AT-A/NT11 or AT-E/NT12 could be the major carrier responsible 222 
for the observed hypoxanthine transport function. However, the knockout of either of these 223 
genes from TbNBT-KO, generating the TbNBT/AT-A-KO and TbNBT/AT-E-KO clonal 224 
lines, did not change the rate of hypoxanthine uptake in comparison to the parental cell line 225 
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TbNBT-KO (Figure 2a), and the average rate in three paired experiments was not 226 
significantly different from TbAT1-KO (P>0.1 by Paired Student’s T-test; Figure 2b). Thus, 227 
we decided to further investigate the transporter responsible for hypoxanthine uptake under 228 
culture conditions. We found that the Km and Vmax values in all three cell lines were very 229 
similar (Table 1), with Km values between 20.2 and 22.9 µM and Vmax between 0.49 and 0.57 230 
pmol(107 cells)-1s-1. These data further support our conclusion that AT-A and AT-E do not 231 
substantially contribute to hypoxanthine transport in cultured bloodstream forms of T. brucei. 232 
We selected the TbNBT/AT-E-KO cell line for further experiments to characterize the 233 
observed hypoxanthine transport activity. Therefore, its Km (22.0 ± 1.7 µM; Figure 3a) was 234 
used for the calculation of Ki values in the below competition assays. 235 
 One strong possibility was that one or more of the P1-like transporters are able to 236 
transport hypoxanthine [15], and we therefore tested whether transport of [3H]-hypoxanthine 237 
could be inhibited by inosine or adenosine, the classical substrates for P1, typically with Km 238 
values close to the 1 µM mark. However, we observed that both inosine and adenosine had 239 
only a minor effect on the transport of [3H]-Hypoxanthine when present in the assay at 240 
concentrations up to 1 mM (P>0.05 by One-way ANOVA, Figure 3b), effectively ruling out 241 
transport through a P1-type transporter. In fact, Figure 3b shows that, in contrast to the 242 
hitherto described kinetoplastid hypoxanthine transporters, this one is highly specific for its 243 
substrate and the transport of 0.1 µM of [3H]-Hypoxanthine could not be completely saturated 244 
by any other natural purine or pyrimidine, or by the hypoxanthine analogue allopurinol. In 245 
fact, all other purines or pyrimidines tested had only a minor effect on the transporter (P>0.05 246 
by One-way ANOVA), even at concentrations as high as 1 mM, i.e. 10,000-fold the radiolabel 247 
concentration. Given that this transporter displays lower affinity that any T. brucei purine 248 
transporter reported to date, and that it is uniquely specific for hypoxanthine, we propose that 249 
it is a new hypoxanthine-specific transporter: HXT1. 250 
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 We investigated whether this transport activity was also present in the s427 wildtype 251 
strain or whether it was somehow a peculiarity of the knockout cell lines. Uptake assays using 252 
s427 wildtype parasites cultured in the same way as the mutant strains, in HMI-9/10% FBS, 253 
and incubated with 0.1 µM of [3H]-hypoxanthine, showed a very similar profile (rate of 254 
uptake of 0.0021 ± 0.0006 pmol(107 cells)-1s-1) to that found in the three knockout cell lines, 255 
and 100 µM of adenine saturated only a minor component of the total hypoxanthine transport 256 
in these cells (rate of uptake 0.0018 ± 0.0006 pmol(107 cells)-1s-1) (P<0.001; Paired Student’s 257 
T-test), proving again it was not one of the known high-affinity nucleobase transporters 258 
previously characterized in bloodstreams grown in vivo (De Koning and Jarvis, 1997b). 259 
However, when s427 cells were cultivated in a nucleobase-limited medium, such as CMM, 260 
the rate of [3H]-hypoxanthine transport was significantly increased (~40%; P<0.001, Unpaired 261 
T-test), and this increase was reversed by 100 µM of adenine (Figure 4). This is consistent 262 
with nucleobase-depleted conditions inducing the expression of (one of) the previously 263 
described high-affinity nucleobase transporters and that their non-expression in culture is an 264 
adaptation to the extremely high hypoxanthine concentration of the HMI-9 medium. 265 
  266 
3.2. Bloodstream forms of T. brucei express an adenine-specific transporter 267 
 The discovery of the novel hypoxanthine transporter HXT1 did not, however, explain 268 
the observations mentioned in the Introduction about non-P2-mediated uptake of melamine-269 
containing molecules, since it displays extremely low affinity for either adenine or adenosine, 270 
nor those about hypoxanthine- and inosine-insensitive but adenine-sensitive adenosine uptake 271 
in TbAT1-KO cells. In order to investigate the presence of such transport, we decided to test 272 
the ability of the knockout cell lines to transport adenine. The use of radiolabelled adenosine 273 
in this model was not suitable because the parasites retain P1 activity, generating a high 274 
background. Since adenine is not a substrate of P1 [18], it should not be transported in the 275 
12 
 
knockout cell lines that also lack TbAT1/P2 and the NT8 cluster, knowing that HXT1 does 276 
not display significant affinity for adenine at 1 mM. However, all the three knockout cell lines 277 
incubated with 0.1 µM of [3H]-Adenine showed the same high level of uptake, which was 278 
linear for at least two minutes (Figure 5), revealing the existence of a high-affinity adenine 279 
transporter. The addition of 1 mM adenine to the reaction completely inhibited the transport 280 
of [3H]-Adenine. 281 
 The transport of [3H]-Adenine in TbNBT/AT-E-KO was performed by a high-affinity 282 
transporter with a Km of 573 ± 62 nM and a Vmax of 0.23 ± 0.06 pmol(107 cells)-1s-1 (n=3) 283 
(Figure 6a), much lower than adenine Ki values previously reported for H2 and H3 (3.2 and 284 
8.8 µM, respectively [19] . As with HXT1, we tested the complete series of natural 285 
nucleobases and nucleosides as inhibitors of the transporter, but none of them inhibited 286 
significantly at 1 mM of inhibitor (P>0.05 by One-way ANOVA, Figure 6b). Based on the 287 
unique Km of this transporter, as well as on its high specificity for adenine, we propose that it 288 
is a new transporter described for T. brucei bloodstream forms, and designate it ADET1. 289 
 290 
3.3. HXT1 and ADET1 are highly specific for their substrates 291 
 In order to better understand the high specificity of HXT1 and ADET1 for their natural 292 
substrates over other natural purines and pyrimidines, we decided to verify which atoms of the 293 
native substrates were involved in the recognition by the transporter. To do so, several 294 
analogues of hypoxanthine and adenine with modifications at different positions of the purine 295 
ring were used in uptake assays in competition to 0.1 µM of [3H]-Hypoxanthine and [3H]-296 
Adenine for transport by HXT1 and ADET1, respectively. 297 
 We found that none of the analogues used, or any substitution made in different 298 
positions of the purine ring, were able to completely inhibit the transport of [3H]-299 
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hypoxanthine or [3H]-adenine by HXT1 or ADET1 at the concentrations tested. Furthermore, 300 
ADET1 showed a much higher specificity for adenine than HXT1 for hypoxanthine (Table 2). 301 
 HXT1 showed to be dependent on the protonation state of N1, given that 6-302 
Chloropurine and 6-Methoxypurine, which each display a single bond with C6, which 303 
corresponds to an unprotonated state of N1, displayed a much lower binding energy than 6-304 
Mercaptopurine, which forms a double bond with C6 and thus keeps N1 in a protonated state; 305 
neither the chloro nor the sulphur at position 6 is capable of forming a significant hydrogen 306 
bond. Interestingly, the addition of a methyl group on position 1 or a Chlorine on position 2 307 
led to the a very similar loss in Gibbs free energy, and it is possible to hypothesize that these 308 
bigger groups may interfere with a possible π-π stacking formed between the transporter and 309 
the aromatic ring, as shown to happen between P2 [1, 18, 33] and Toxoplasma gondii AT2 310 
[49] and their natural substrates. 311 
 Also, N7 seems to have a small participation in the interaction with HXT1, given that 312 
its removal from the ring leads to a loss of 2.5 KJ/mol in Gibbs free energy. When the 313 
Nitrogen is dislocated from position 7 to position 8 in Allopurinol, a much higher loss of 314 
energy is identified. The presence of a Nitrogen on position 8 seems to have a repulsive effect 315 
in the binding pocket probably due to the arrangement of the compound within the binding 316 
pocket, which may lead to interaction with a different amino acid, and consequent repulsion, 317 
which is diminished by the simultaneous presence of N7, as seen in 8-Azahypoxanthine, 318 
occasioning a recovery of 4.8 KJ/mol in Gibbs free energy, highlighting the participation of 319 
N7 in the binding to the transporter. 320 
 Moreover, N9 is also important in the binding to HXT1 since its replacement by a 321 
Carbon in the purine ring (9-Deazahypoxanthine) causes a loss of 3.5 KJ/mol in this 322 
interaction, in agreement with the extremely low affinity HXT1 has for inosine, with IC50 323 
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above 2.5mM. Furthermore, it is very likely that HXT1 has a tight binding pocket that cannot 324 
easily accommodate nucleosides. 325 
 ADET1 seems to have the same characteristic of tight binding pocket, although it can 326 
accommodate 2-deoxyadenosine when at very high concentration (Ki of 1352 ± 279 µM). The 327 
higher affinity for 2’-deoxyadenosine compared to adenosine also shows that the ribose group 328 
is not part of the interaction and its presence may perturb the transport. The same 329 
characteristic has been shown for P2: the lack of affinity for the ribose makes it a burden for 330 
the transporter, and the reduction in the size of the ribose group, by removal of hydroxyl 331 
groups, lead to higher rate of transport [18]. 332 
 The affinity of ADET1 for its substrate is also much higher than that seen for HXT1 333 
and hypoxanthine, which is also translated into a much lower Km for ADET1. This high 334 
affinity is also noticed by the great loss of energy of interaction every time a modification is 335 
made in the purine ring. More importantly, N7 and the amino group attached to C6 seem to be 336 
of particular importance for transport via ADET1, since their removal caused the biggest 337 
losses of Gibbs free energy, as seen for 6-Chloropurine, 6-Mercaptopurine and 7-338 
Deazaadenine: 16.1, 16 and 17.1 KJ/mol, respectively. Moreover, the shift of the Nitrogen 339 
from position 7 to position 8 of the imidazole ring in Aminopurinol caused a lower loss of 340 
energy than that seen for 7-Deazaadenine, showing the Nitrogen on position 8 might weakly 341 
interact with the transporter, recovering 4.4 kJ/mol in binding energy in comparison to 7-342 
Deazaadenine. 343 
 344 
4. DISCUSSION 345 
 Nutrient transport mechanisms are present in all types of living cells, playing a vital 346 
role in maintaining cell viability and the progression of the cell cycle. Among these nutrients, 347 
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purines and pyrimidines are of major importance as they are the basis for nucleic synthesis, 348 
and serve as cofactors and metabolic intermediates. 349 
 While most mammalian cells can synthesize their own purines and pyrimidines, 350 
protozoan parasites, such as trypanosomatids and apicomplexans, can synthesize only 351 
pyrimidines de novo and obtain purines solely by salvage from the host [1]. Due to a complex 352 
network of pathways, trypanosomatids can interconvert purines, being able to generate all 353 
needed nucleotides from any single purine source [50]. Given the essentiality of purine 354 
transport mechanisms for these parasites, many pharmacological approaches have targeted 355 
these proteins as drug carriers for antiparasitic treatments. It is thus clear that (some) purine 356 
transporters can in principle be exploited for the effective import of cytotoxins, selectively 357 
into the parasite if such molecules are specifically designed to interact with this transporter 358 
[10, 38-40, 51].  359 
 The T. brucei purine transporters seem to be encoded by at least a dozen ENT genes, 360 
which have now been largely characterised [8, 15, 16, 20-22]. However, work from Michael 361 
Barrett’s group [41] revealed the potential existence of additional and as yet uncharacterised 362 
purine transport mechanisms in T. brucei, which we here investigate by deleting all ENT 363 
genes except the P1-type adenosine/inosine transporters. We report two novel, unusual purine 364 
transport activities expressed in bloodstream forms of the parasite: a relatively low affinity 365 
hypoxanthine-specific transporter and a very high affinity adenine-specific transporter, each 366 
with no affinity for any other natural purine or pyrimidine except their primary substrate, even 367 
at concentrations far above physiological levels. These carriers are likely the final pieces in 368 
the substantial array trypanosomes can employ to fine-tune the uptake of specific purines 369 
from their very diverse environments during the life cycle. 370 
 The great majority of purine transporters have selectivity over a range of substrates, as 371 
seen in humans (ENT1, ENT2 and ENT3 [52]), Leishmania spp. [9, 53, 54], and T. brucei [4, 372 
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8, 18-20], among others. Although quite uncommon in nature, purine transporters with high 373 
specificity for their substrates have been reported: CfAT1 for adenosine in the trypanosomatid 374 
Crithidia fasciculata [55] and FcyD for adenine in the fungus Aspergillus nidulans [56], but it 375 
is a novelty for T. brucei. Interestingly, Krypotou et al. (2015) demonstrated the independent 376 
emergence of Fcy-like transporters in fungi as a class apart from other NCS1 (Nucleobase 377 
Cation Symporter 1)–encoding organisms [57], and more recently it was shown that FcyD 378 
sequences exist only in a very narrow cluster of fungi related to A. nidulans [56], and 379 
therefore is unlikely to have any relation with either C. fasciculata AT1 or the herein 380 
described T. brucei transporters HXT1 and ADET1. Indeed, our searches for analogous 381 
sequences in the T. brucei genome databases did not yield any candidate genes in this family 382 
(results not shown). Moreover, FcyD seems to be rarely expressed and could not be detected 383 
under laboratory conditions, but may play a potential role in the life cycle of A. nidulans in its 384 
natural habitat [56]. It is possible to argue that at least HXT1 follows this logic in an opposite 385 
way: it is expressed under laboratory conditions, but was not detected in bloodstream forms 386 
isolated from rat blood, because under those conditions higher affinity nucleobase transporters 387 
were expressed as fits the relatively purine-poor conditions of serum [19]. As for ADET1, this 388 
was not previously detected for the simple reason that previous studies all used radiolabelled 389 
hypoxanthine or adenosine instead of adenine. We are currently assessing whether either 390 
transporter is expressed in the procyclic life-cycle stage but, not knowing the genetic identity, 391 
cannot easily discern their expression levels under many different conditions. 392 
  In fact, the purine nucleobase transport mechanisms described for bloodstream forms 393 
of T. brucei were originally characterized in parasites isolated from infected rats [19, 47], and 394 
not from parasites obtained from axenic culture, and it has become clear that the expression 395 
levels of some of the transporters, including P2 [58], is much lower in the long-term cultured 396 
cells. If we consider the fact that the commonly used culture medium for bloodstream forms, 397 
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HMI-9, contains 1 mM hypoxanthine, and that the transport of purines in trypanosomatids is 398 
proton-dependent [4-6], and coupled to a plasma membrane H+-ATPase to avoid cytoplasmic 399 
acidification [4, 5], it is unsurprising that the cells drastically reduce the level of expression of 400 
such high-affinity transporters, in order to avoid unnecessarily high levels of hypoxanthine 401 
uptake. Indeed, it has previously been established that high affinity hypoxanthine (and 402 
adenosine) uptake in T. brucei bloodstream forms is correlated to the extracellular purine 403 
concentration and the cell cycle [59], as is the case for purine transport in the related parasite 404 
Crithidia luciliae [60]. 405 
 In the current manuscript we show that the transport of hypoxanthine in axenic culture 406 
is mostly driven by HXT1, a medium-affinity, low capacity hypoxanthine-specific transporter 407 
(Km 22 ± 1.73 µM; Vmax 0.49 ± 0.06 pmol(107 cells)-1s-1), as rates hardly changed by knockout 408 
of the three NT8 genes that encode high-affinity broad specificity nucleobase transporters [20, 409 
21]. When cells were transferred to a medium depleted of nucleobases, such as CMM, the 410 
level of expression of the adenine-sensitive hypoxanthine transporters was elevated, which 411 
translated into a higher level of uptake of this nucleobase. Interestingly, the higher expression 412 
of the adenine-sensitive H2 and/or H3 transporters was not followed by a reduction in 413 
expression of HT1, given that the addition of 100 µM adenine to the uptake assay buffer re-414 
established the hypoxanthine uptake to those found in the knockout cell lines (TbNBT-KO, 415 
TbNBT/AT-A-KO and TbNBT/AT-E-KO) and very close to that verified for s427 cultivated 416 
in HMI-9.  417 
 The transport of adenine remained very high in the NBT-knockout cell lines, and was 418 
mediated by a new high-affinity adenine-specific transporter we designate ADET1, which has 419 
no prominent affinity for any other purine or pyrimidine tested, and due to its lack of affinity 420 
for hypoxanthine, it is unsurprising that it is not downregulated by maintenance of cells in 421 
HMI-9, which contains only the trace amounts of adenine from the foetal bovine serum. 422 
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 Considering the high-fidelity shown by HXT1 and ADET1 for their substrates, they 423 
must bind hypoxanthine and adenine, respectively, in a very unique way. And in fact, it seems 424 
to be so unique that almost any modification or addition to the purine ring disturbs the 425 
interaction with the transporter. None of the adenine analogues tested inhibited ADET1-426 
mediated [3H]-adenine transport completely, and this translates into a very substantial loss in 427 
Gibbs free energy of binding relative to adenine. The extent of the loss of binding energy 428 
might be occasioned by different reasons. First, there may be a certain level of cooperativity 429 
between the hydrogen bonds formed between adenine and ADET1, as described for P1 in T. 430 
brucei, and the loss of one point of interaction my affect the formation of other bonds [18]. 431 
Secondly, it is possible to argue that a modification in the substrate may alter the orientation 432 
of this molecule in the binding pocket which occasions a different mode of interaction, as 433 
described for the UapA transporter from A. nidulans, in which xanthine and its analogue 434 
oxypurinol enter the binding pocket in different orientations [61]. Thirdly, the architecture of 435 
a transporter is quite complex and not completely understood. One accepted theory is the 436 
presence of intra and extracellular gates that participate in the interaction between the 437 
transporter and its substrate and also in the dynamic of transport. In this model, in order to 438 
enter the cell, a substrate would have to interact with the extracellular gate and lead to a 439 
conformational change, allowing this substrate to slide down and then interact with the 440 
binding pocket, which will translocate the substrate to intracellular environment [62]. It could 441 
be hypothesized that HXT1 and especially ADET1 may present extracellular gates and 442 
binding pockets that recognize different motifs of the substrates.  443 
 In summary, we described and characterized two highly specific carriers for purine 444 
nucleobases in T. brucei bloodstream forms under standard culture conditions. These 445 
transporters were in evidence in strains from which all ENT genes, except the P1 inosine-446 
sensitive sub-class, had been deleted and it is thus highly unlikely that they are encoded for by 447 
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a gene of that family. This would constitute the first evidence of purine uptake by a non-ENT 448 
transporter in a protozoan, although we have previously argued that the pyrimidine 449 
nucleobase transporters LmajU1 and TbU1 [63, 64] must also be from a different family than 450 
ENT [24]. Interestingly, these pyrimidine nucleobase transporters are also extremely selective 451 
for one nucleobase only, uracil. The cloning of these transporters will establish whether U1, 452 
HXT1 and ADET1 are from the same family and whether this is limited to kinetoplastid 453 
protozoa.  454 
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Table 1. HXT1 kinetics determined in TbNBT-KO, TbNBT/AT-E-KO and TbNBT/AT-A-462 
KO 463 
 464 
Cell line Km Vmax 
TbNBT-KO 20.2 ± 5 0.57 ± 0.13 
TbNBT/AT-E-KO 22.0 ± 1.7 0.49 ± 0.06 
TbNBT/AT-A-KO 22.9 ± 4.2 0.53 ± 0.07 
Km values are expressed in µM and Vmax in pmol.107cells.s-1. 465 
  466 
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Table 2. Ki values for potential inhibitors of hypoxanthine and adenine transport mediated by 467 
HXT1 and A1 468 
1×107 cells were incubated with 0.1µM of tritiated substrates for one minute in presence of increasing concentrations of inhibitor. IC50 values 469 
obtained were converted to Ki based on the Km of each transporter. All the averages and standard deviations are based on at least three 470 
independent experiments in triplicate. 471 
Compound 
HTX1  ADET1 
Ki ΔG0 δ(ΔG0)  Ki ΔG0 δ(ΔG0) 
Hypoxanthine 22.0 ± 1.71 -26.6 --  >1000   
Adenine >1000    0.57 ± 0.061 -35.6 -- 
1-Deazaadenine N.D.    72.9 ± 2.0 -23.6 -12.0 
1-Methylhypoxanthine 56.2 ± 6.1 -24.2 -2.4  N.D.   
2-Chlorohypoxanthine 47.6 ± 2.5 -24.7 -1.9  N.D.   
2,6-Diaminopurine N.D.    177.04 ± 8.0 -21.4 -14.2 
6-Chloropurine 330.6 ± 20.9 -19.9 -6.7  378.7 ± 11.4 -19.5 -16.1 
6-Methoxypurine 315.4 ± 33.6 -20 -6.6  N.D.   
6-Mercaptopurine 34.4 ± 1.1 -25.5 -1.1  362.8 ± 9.4 -19.6 -16 
7-Deazaadenine N.D.    561.1 ± 5.6 -18.5 -17.1 
7-Deazahypoxanthine 58.8 ± 8.4 -24.1 -2.4  N.D.   
8-Azahypoxanthine 67.9 ± 11.5 -23.8 -2.8  N.D.   
9-Deazaadenine N.D.    46.9 ± 2.4 -24.7 -10.9 
9-Deazahypoxanthine 46.6 ± 3.5 -23.5 -3.1  N.D.   
Allopurinol 469.5 ± 4.1 -19 -7.6  N.D.   
Aminopurinol N.D.    94.9 ± 4.0 -23 -12.7 
2’-Deoxyadenosine N.D.    1352 ± 280 -16.4 -19.2 
1Km value 472 
N.D. – Not determined. 473 
  474 
22 
 
7. REFERENCES 475 
[1] de Koning HP, Bridges DJ, Burchmore RJS. Purine and pyrimidine transport in pathogenic 476 
protozoa: From biology to therapy. Fems Microbiology Reviews. 2005;29:987-1020. 477 
[2] Molina-Arcas M, Casado FJ, Pastor-Anglada M. Nucleoside Transporter Proteins. Curr Vasc 478 
Pharmacol. 2009;7:426-34. 479 
[3] Choi JS, Berdis AJ. Nucleoside transporters: biological insights and therapeutic applications. Future 480 
Med Chem. 2012;4:1461-78. 481 
[4] de Koning HP, Jarvis SM. Hypoxanthine uptake through a purine-selective nucleobase transporter 482 
in Trypanosoma brucei brucei procyclic cells is driven by protonmotive force. European Journal of 483 
Biochemistry. 1997;247:1102-10. 484 
[5] de Koning HP, Watson CJ, Jarvis SM. Characterization of a nucleoside/proton symporter in 485 
procyclic Trypanosoma brucei brucei. J Biol Chem. 1998;273:9486-94. 486 
[6] Stein A, Vaseduvan G, Carter NS, Ullman B, Landfear SM, Kavanaugh MP. Equilibrative nucleoside 487 
transporter family members from Leishmania donovani are electrogenic proton symporters. J Biol 488 
Chem. 2003;278:35127-34. 489 
[7] de Koning H, Diallinas G. Nucleobase transporters (review). Mol Membr Biol. 2000;17:75-+. 490 
[8] Al-Salabi MI, Wallace LJM, Luscher A, Maser P, Candlish D, Rodenko B, et al. Molecular 491 
interactions underlying the unusually high adenosine affinity of a novel Trypanosoma brucei 492 
nucleoside transporter. Mol Pharmacol. 2007;71:921-9. 493 
[9] Alzahrani KJH, Ali JAM, Eze AA, Looi WL, Tagoe DNA, Creek DJ, et al. Functional and genetic 494 
evidence that nucleoside transport is highly conserved in Leishmania species: Implications for 495 
pyrimidine-based chemotherapy. International Journal for Parasitology-Drugs and Drug Resistance. 496 
2017;7:206-26. 497 
[10] Wallace LJM, Candlish D, Hagos A, Seley KL, de Koning HP. Selective transport of a new class of 498 
purine antimetabolites by the protozoan parasite Trypanosoma brucei. Nucleosides Nucleotides & 499 
Nucleic Acids. 2004;23:1441-4. 500 
[11] Barrett MP, Gilbert IH. Targeting of toxic compounds to the trypanosome's interior. Adv Parasit. 501 
2006;63:125-83. 502 
[12] Berg M, Kohl L, Van der Veken P, Joossens J, Al-Salabi MI, Castagna V, et al. Evaluation of 503 
Nucleoside Hydrolase Inhibitors for Treatment of African Trypanosomiasis. Antimicrob Agents Ch. 504 
2010;54:1900-8. 505 
[13] Rodenko B, de Koning HP. Rational Selection of Anti-Microbial Drug Targets: Unique or 506 
Conserved? Trypanosomatid Diseases: Molecular Routes to Drug Discovery. 2013:281-96. 507 
[14] Vodnala SK, Lundback T, Yeheskieli E, Sjoberg B, Gustavsson AL, Svensson R, et al. Structure-508 
Activity Relationships of Synthetic Cordycepin Analogues as Experimental Therapeutics for African 509 
Trypanosomiasis. Journal of Medicinal Chemistry. 2013;56:9861-73. 510 
[15] Sanchez MA, Tryon R, Green J, Boor J, Landfear SM. Six related nucleoside/nucleobase 511 
transporters from Trypanosoma brucei exhibit distinct biochemical functions. J Biol Chem. 512 
2002;277:21499-504. 513 
[16] Sanchez MA, Drutman S, van Ampting M, Matthews K, Landfear SM. A novel purine nucleoside 514 
transporter whose expression is up-regulated in the short stumpy form of the Trypanosoma brucei 515 
life cycle. Mol Biochem Parasit. 2004;136:265-72. 516 
[17] Carter NS, Fairlamb AH. Arsenical-Resistant Trypanosomes Lack an Unusual Adenosine 517 
Transporter. Nature. 1993;361:173-6. 518 
[18] De Koning HP, Jarvis SM. Adenosine transporters in bloodstream forms of Trypanosoma brucei 519 
brucei: Substrate recognition motifs and affinity for trypanocidal drugs. Mol Pharmacol. 520 
1999;56:1162-70. 521 
[19] de Koning HP, Jarvis SM. Purine nucleobase transport in bloodstream forms of Trypanosoma 522 
brucei brucei is mediated by two novel transporters. Mol Biochem Parasit. 1997;89:245-58. 523 
23 
 
[20] Burchmore RJS, Wallace LJM, Candlish D, Al-Salabi MI, Beal PR, Barrett MP, et al. Cloning, 524 
heterologous expression, and in situ characterization of the first high affinity nucleobase transporter 525 
from a protozoan. J Biol Chem. 2003;278:23502-7. 526 
[21] Henriques C, Sanchez MA, Tryon R, Landfear SM. Molecular and functional characterization of 527 
the first nucleobase transporter gene from African trypanosomes. Mol Biochem Parasit. 528 
2003;130:101-10. 529 
[22] Ortiz D, Sanchez MA, Quecke P, Landfear SM. Two novel nucleobase/pentamidine transporters 530 
from Trypanosoma brucei. Mol Biochem Parasit. 2009;163:67-76. 531 
[23] Bellofatto V. Pyrimidine transport activities in trypanosomes. Trends Parasitol. 2007;23:187-9. 532 
[24] de Koning HP. Pyrimidine transporters of trypanosomes - a class apart? Trends Parasitol. 533 
2007;23:190-. 534 
[25] Maser P, Sutterlin C, Kralli A, Kaminsky R. A nucleoside transporter from Trypanosoma brucei 535 
involved in drug resistance. Science. 1999;285:242-4. 536 
[26] de Koning HP, MacLeod A, Barrett MP, Cover B, Jarvis SM. Further evidence for a link between 537 
melarsoprol resistance and P2 transporter function in African trypanosomes. Mol Biochem Parasit. 538 
2000;106:181-5. 539 
[27] Matovu E, Stewart ML, Geiser F, Brun R, Maser P, Wallace LJM, et al. Mechanisms of arsenical 540 
and diamidine uptake and resistance in Trypanosoma brucei. Eukaryotic Cell. 2003;2:1003-8. 541 
[28] de Koning HP, Jarvis SM. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by 542 
the P2 adenosine transporter and at least one novel, unrelated transporter. Acta Trop. 2001;80:245-543 
50. 544 
[29] de Koning HP, Anderson LF, Stewart M, Burchmore RJS, Wallace LJM, Barrett MP. The 545 
trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine 546 
transporter: additional insights on diamidine resistance in African trypanosomes. Antimicrob Agents 547 
Ch. 2004;48:1515-9. 548 
[30] Teka IA, Kazibwe AJN, El-Sabbagh N, Al-Salabi MI, Ward CP, Eze AA, et al. The Diamidine 549 
Diminazene Aceturate Is a Substrate for the High-Affinity Pentamidine Transporter: Implications for 550 
the Development of High Resistance Levels in Trypanosomes. Mol Pharmacol. 2011;80:110-6. 551 
[31] Munday JC, Lopez KER, Eze AA, Delespaux V, Van den Abbeele J, Rowan T, et al. Functional 552 
expression of TcoAT1 reveals it to be a P1-type nucleoside transporter with no capacity for 553 
diminazene uptake. International Journal for Parasitology-Drugs and Drug Resistance. 2013;3:69-76. 554 
[32] Collar C, Al Salabi M, Stewart M, Barrett M, Wilson D, De Koning H. Molecular modelling of 555 
substrate recognition at an unusual aminopurine transporter. Purinergic Signalling. 2010;6:12-. 556 
[33] Munday JC, Tagoe DNA, Eze AA, Krezdorn JAM, Lopez KER, Alkhaldi AAM, et al. Functional 557 
analysis of drug resistance-associated mutations in the Trypanosoma brucei adenosine transporter 1 558 
(TbAT1) and the proposal of a structural model for the protein. Mol Microbiol. 2015;96:887-900. 559 
[34] de Koning HP. Uptake of pentamidine in Trypanosoma brucei brucei is mediated by three 560 
distinct transporters: Implications for cross-resistance with arsenicals. Mol Pharmacol. 2001;59:586-561 
92. 562 
[35] Bridges DJ, Gould MK, Nerima B, Maser P, Burchmore RJS, de Koning HP. Loss of the high-affinity 563 
pentamidine transporter is responsible for high levels of cross-resistance between arsenical and 564 
diamidine drugs in African trypanosomes. Mol Pharmacol. 2007;71:1098-108. 565 
[36] Baker N, Glover L, Munday JC, Andres DA, Barrett MP, de Koning HP, et al. Aquaglyceroporin 2 566 
controls susceptibility to melarsoprol and pentamidine in African trypanosomes. P Natl Acad Sci USA. 567 
2012;109:10996-1001. 568 
[37] Munday JC, Eze AA, Baker N, Glover L, Clucas C, Andres DA, et al. Trypanosoma brucei 569 
aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs 570 
and the main genetic determinant of resistance to these drugs. Journal of Antimicrobial 571 
Chemotherapy. 2014;69:651-63. 572 
[38] Stewart ML, Bueno GJ, Baliani A, Klenke B, Brun R, Brock JM, et al. Trypanocidal activity of 573 
melamine-based nitroheterocycles. Antimicrob Agents Chemother. 2004;48:1733-8. 574 
24 
 
[39] Stewart ML, Boussard C, Brun R, Gilbert IH, Barrett MP. Interaction of monobenzamidine-linked 575 
trypanocides with the Trypanosoma brucei P2 aminopurine transporter. Antimicrob Agents Ch. 576 
2005;49:5169-71. 577 
[40] Tye CK, Kasinathan G, Barrett MP, Brun R, Doyle VE, Fairlamb AH, et al. An approach to use an 578 
unusual adenosine transporter to selectively deliver polyamine analogues to trypanosomes. Bioorg 579 
Med Chem Lett. 1998;8:811-6. 580 
[41] Stewart ML. The role of the P2 purine transporter in drug uptake and resistance in 581 
trypanosomes. PhD thesis, University of Glasgow. 2003. 582 
[42] Gudin S, Quashie NB, Candlish D, Al-Salabi MI, Jarvis SM, Ranford-Cartwright LC, et al. 583 
Trypanosoma brucei: A survey of pyrimidine transport activities. Exp Parasitol. 2006;114:118-25. 584 
[43] Creek DJ, Nijagal B, Kim DH, Rojas F, Matthews KR, Barrett MP. Metabolomics Guides Rational 585 
Development of a Simplified Cell Culture Medium for Drug Screening against Trypanosoma brucei. 586 
Antimicrob Agents Ch. 2013;57:2768-79. 587 
[44] Burchmore RJS, Rodriguez-Contreras D, McBride K, Barrett MP, Modi G, Sacks D, et al. Genetic 588 
characterization of glucose transporter function in Leishmania mexicana. P Natl Acad Sci USA. 589 
2003;100:3901-6. 590 
[45] Scahill MD, Pastar I, Cross GAM. CRE recombinase-based positive-negative selection systems for 591 
genetic manipulation in Trypanosoma brucei. Mol Biochem Parasit. 2008;157:73-82. 592 
[46] Cross M, Kieft R, Sabatini R, Dirks-Mulder A, Chaves I, Borst P. J-binding protein increases the 593 
level and retention of the unusual base J in trypanosome DNA. Mol Microbiol. 2002;46:37-47. 594 
[47] Wallace LJM, Candlish D, De Koning HP. Different substrate recognition motifs of human and 595 
trypanosome nucleobase transporters - Selective uptake of purine antimetabolites. J Biol Chem. 596 
2002;277:26149-56. 597 
[48] Cheng Y, Prusoff WH. Relationship between Inhibition Constant (K1) and Concentration of 598 
Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic-Reaction. Biochem Pharmacol. 599 
1973;22:3099-108. 600 
[49] De Koning HP, Al-Salabi MI, Cohen AM, Coombs GH, Wastling JM. Identification and 601 
characterisation of high affinity nucleoside and nucleobase transporters in Toxoplasma gondii. Int J 602 
Parasitol. 2003;33:821-31. 603 
[50] Boitz JM, Ullman B, Jardim A, Carter NS. Purine salvage in Leishmania: complex or simple by 604 
design? Trends Parasitol. 2012;28:345-52. 605 
[51] Rodenko B, Wanner MJ, Alkhaldi AAM, Ebiloma GU, Barnes RL, Kaiser M, et al. Targeting the 606 
Parasite's DNA with Methyltriazenyl Purine Analogs Is a Safe, Selective, and Efficacious 607 
Antitrypanosomal Strategy. Antimicrob Agents Ch. 2015;59:6708-16. 608 
[52] Young JD, Yao SYM, Baldwin JM, Cass CE, Baldwin SA. The human concentrative and equilibrative 609 
nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med. 2013;34:529-47. 610 
[53] Aronow B, Kaur K, Mccartan K, Ullman B. Two High-Affinity Nucleoside Transporters in 611 
Leishmania donovani. Mol Biochem Parasit. 1987;22:29-37. 612 
[54] Carter NS, Drew ME, Sanchez M, Vasudevan G, Landfear SM, Ullman B. Cloning of a novel 613 
inosine-guanosine transporter gene from Leishmania donovani by functional rescue of a transport-614 
deficient mutant. J Biol Chem. 2000;275:20935-41. 615 
[55] Arendt CS. Crithidia fasciculata adenosine transporter 1 (CfAT1), a novel high-affinity 616 
equilibrative nucleoside transporter specific for adenosine. Mol Biochem Parasit. 2013;191:75-9. 617 
[56] Sioupouli G, Lambrinidis G, Mikros E, Amillis S, Diallinas G. Cryptic purine transporters in 618 
Aspergillus nidulans reveal the role of specific residues in the evolution of specificity in the NCS1 619 
family. Mol Microbiol. 2017;103:319-32. 620 
[57] Krypotou E, Evangelidis T, Bobonis J, Pittis AA, Gabaldon T, Scazzocchio C, et al. Origin, 621 
diversification and substrate specificity in the family of NCS1/FUR transporters. Mol Microbiol. 622 
2015;96:927-50. 623 
[58] Ward CP, Wong PE, Burchmore RJ, de Koning HP, Barrett MP. Trypanocidal Furamidine 624 
Analogues: Influence of Pyridine Nitrogens on Trypanocidal Activity, Transport Kinetics, and 625 
Resistance Patterns. Antimicrob Agents Ch. 2011;55:2352-61. 626 
25 
 
[59] de Koning HP, Watson CJ, Sutcliffe L, Jarvis SM. Differential regulation of nucleoside and 627 
nucleobase transporters in Crithidia fasciculata and Trypanosoma brucei brucei. Mol Biochem 628 
Parasit. 2000;106:93-107. 629 
[60] Hall ST, Hillier CJ, Gero AM. Crithidia luciliae: Regulation of purine nucleoside transport by 630 
extracellular purine concentrations. Exp Parasitol. 1996;83:314-21. 631 
[61] Diallinas G. Allopurinol and xanthine use different translocation mechanisms and trajectories in 632 
the fungal UapA transporter. Biochimie. 2013;95:1755-64. 633 
[62] Diallinas G. Understanding transporter specificity and the discrete appearance of channel-like 634 
gating domains in transporters. Front Pharmacol. 2014;5. 635 
[63] de Koning HP, Jarvis SM. A highly selective, high-affinity transporter for uracil in Trypanosoma 636 
brucei brucei: evidence for proton-dependent transport. Biochem Cell Biol. 1998;76:853-8. 637 
[64] Papageorgiou IG, Yakob L, Al Salabi MI, Diallinas G, Soteriadou KP, De Koning HP. Identification 638 
of the first pyrimidine nucleobase transporter in Leishmania: similarities with the Trypanosoma 639 
brucei U1 transporter and antileishmanial activity of uracil analogues. Parasitology. 2005;130:275-83. 640 
 641 
  642 
26 
 
Figure Legends 643 
 644 
Figure 1. A. Construction of high-affinity nucleobase transporter null mutant. A. Strategy for 645 
target gene replacement. The genomic locus containing two 40S ribosomal protein, three 646 
nucleobase transporters and a hypothetical protein encoding genes are shown. The unique 5’ 647 
used in the knockout cassette was cloned as part of the 40S ribosomal protein (373 bp) and 648 
part of the UTR next to it (101 bp). A unique sequence for the 3’ followed the same logic: 649 
part of UTR and part of the hypothetical protein gene Tb927.11.3640 were amplified by PCR 650 
and inserted into the knockout cassette in pyr-FEKO vector, containing a resistance marker, a 651 
thymidine kinase (TK) and loxP sequences (black boxes), which enable the removal of the 652 
cassette. B. PCR showing the presence of ORFs for nucleobase transporters in TbAT1-KO 653 
(parent cell line), heterozygous knockout line after the first round of knockout (TbNBT-sKO), 654 
and their absence after the complete knockout of the whole genomic locus (TbNBT-KO). The 655 
presence of DNA in the reaction is confirmed by the amplification of a 400bp fragment of 656 
actin. NC – Negative Control.  657 
 658 
Figure 2. Time course for 3H-Hypoxanthine uptake. Cells were incubated with 0.1 µM of 3H-659 
Hypoxanthine in absence (closed symbols) or presence (open symbols) of 1 mM of unlabelled 660 
hypoxanthine (Hx). A. Transport of 3H-Hypoxanthine was not altered, either by the knockout 661 
of high-affinity hypoxanthine transporters or by deletion of AT-E or AT-A. Graph shows 662 
mean ± standard deviation of three or more independent experiments in triplicate. B. 663 
Comparison between TbAT1-KO and nucleobase transporter knockout cell lines for uptake of 664 
3H-Hypoxanthine: no statistical relevance was found by comparing. 665 
 666 
Figure 3. A. Rate of transport was determined by incubation of TbNBT/AT-E-KO with 667 
0.1µM of 3H-Hypoxanthine in presence of 0 – 1 mM of unlabelled hypoxanthine (inset). 668 
Conversion of inhibition data into a Michaelis-Menten plot yielded a Km value of 22.0 ± 1.7 669 
µM and a Vmax of 0.49 ± 0.06 pmol(107 cells)-1s-1. Graph shows one representative out of 670 
three independent experiments in triplicate. B. Presence of 1 mM of natural purines and 671 
pyrimidines in the transport assay buffer did not significantly alter the uptake of 0.1 µM 3H-672 
Hypoxanthine (n=3). Due to solubility limitations, guanine was used as inhibitor at 25 μM 673 
(n=2). 674 
 675 
Figure 4. s427 wildtype parasites cultivated in HMI-9 present a level of hypoxanthine uptake 676 
close to TbNBT-KO. The addition of 100 µM of adenine to the transport assay buffer slightly 677 
altered the rate of transport. When cells were cultivated with virtually no nucleobases in 678 
CMM (see Materials and Methods), the rate of uptake of 3H-Hypoxanthine was increased by 679 
about 40%, which could be reduced to the same level as in TbNBT-KO by addition of adenine 680 
to the transport assay buffer. Figure shows one representative experiment in triplicate. 681 
 682 
Figure 5. A. Time course for the uptake of 0.1µM of 3H-Adenine in TbAT1-KO (circles), 683 
TbNBT-KO (squares), TbNBT/AT-E-KO (up triangles) and TbNBT/AT-A-KO (down 684 
triangles) in absence (closed symbols) or presence (open symbols) of 1 mM of unlabelled 685 
adenine. The graph shows mean ± standard deviation of three independent experiments in 686 
triplicate. B. Comparison between TbAT1-KO and nucleobase transporter knockout cell lines 687 
for uptake of 3H-Adenine. Among the three new knockout cell lines generated, only 688 
TbNBT/AT-E-KO presented a rate of 3H-Adenine uptake significantly different from TbAT1-689 
KO (P=0.04; Paired T-test). 690 
 691 
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Figure 6. A. Rate of uptake was determined by incubation of TbNBT/AT-E-KO with 0.1µM 692 
of 3H-Adenine in presence of 0–1 mM of unlabelled adenine (inset). Inhibition data were 693 
converted into a Michaelis-Menten plot yielding a Km of 573 ± 62 nM and a Vmax of 0.228 ± 694 
0.006 pmol(107 cells)-1s-1. Graph shows one representative out of three independent 695 
experiments in triplicate. B. Addition of natural purines and pyrimidines in the transport assay 696 
buffer at concentrations as high as 1mM could not completely inhibit the uptake of 0.1µM 3H-697 
Adenine (n=3). Due to solubility limitations, guanine was assayed at 25 μM (n=2). 698 
